A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan
Phase of Trial: Phase IV
Latest Information Update: 02 Nov 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 16 Oct 2018 Planned End Date changed from 31 Jan 2018 to 29 Mar 2019.
- 16 Oct 2018 Planned primary completion date changed from 31 Jan 2018 to 18 Dec 2018.
- 14 Feb 2018 Status changed to active, no longer recruiting.